Abstract

Introduction: Benign breast diseases are often considered as aberrations of normal development and involution. The increasing campaigns for breast health have increased awareness among women causing an increase in the number of cases detected. Around 70%–80% of the biopsies performed are of benign nature. The most common complaints are lump, pain, and discharge. Aim: Our primary aim was to study the clinicopathological correlation of benign breast disease and view it in the context of other similar studies in the past. Materials and Methods: Sixty patients attending the Outpatient and Inpatient Department of Surgery at a tertiary care hospital from June 2011 to December 2012 was carried out. Various parameters such as age, sex, disease pattern, lesion types, histopathological diagnosis, and clinical diagnosis were studied and compared. Cramer's V test was applied. Results: In our study, fibroadenoma (66.7%) was the most common lesion which occurred in patients in the age group of 21–30 years, followed by fibroadenosis (16.7%) which occurred mostly in the age group of 21–30 years. The lesion mostly occurred in the age group between 21 and 30 years (40%). The most common complaint in women was lump (73.33%), followed by lump and pain. Conclusions: Epidemiology of benign breast diseases still remains the same when analyzed with a past and recent study on benign breast diseases. Triple assessment remains the key in the evaluation of breast lumps.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.